Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT04308616 Completed - Psoriasis Clinical Trials

Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis

SCCAPSO
Start date: July 20, 2020
Phase:
Study type: Observational

Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.

NCT ID: NCT04307654 Completed - Clinical trials for Lactacidemia and Complications

Lactate and Complications in Cytoreduction Surgery for Peritoneal Carcinomatosis

Start date: January 2014
Phase:
Study type: Observational

Serum lactate is a risk factor for postoperative complications in patients undergoing cytoreduction surgery in peritoneal carcinomatosis

NCT ID: NCT04303286 Completed - Clinical trials for Hepatocellular Carcinoma

The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma

Start date: October 1, 2018
Phase:
Study type: Observational

The purpose of this study was to explore the correlation between postoperative recovery of liver function and gut microbiota in patients with hepatocellular carcinoma (HCC). Liver resection patients were divided into the recovery group and the recovery delay group according to the recovery level of liver function on the fifth day after the operation. Benign liver disease was used as a control. Statistical analysis was performed to compare the differences in gut microbiota between the three groups. Then, fecal microbiota transplantation was performed in a mouse hepatectomy model. Through this study, the investigators hope to understand the relationship between gut microbiota and postoperative recovery of liver function in patients with hepatocellular carcinoma, so as to provide a new therapeutic direction for patients in the aspect of perioperative liver function recovery.

NCT ID: NCT04297384 Completed - Breast Carcinoma Clinical Trials

Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

Start date: February 6, 2019
Phase: N/A
Study type: Interventional

This trial studies the impact of the breast cancer pathways program on the patient experience, including decision making and quality of life. Measuring how the breast cancer pathways program affects decision making and quality of life in patients may help doctors improve cancer education.

NCT ID: NCT04297254 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Start date: February 4, 2021
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the safety of lenvatinib in HCC.

NCT ID: NCT04296058 Completed - Clinical trials for Translational Research of SOX4 in Hepatocellular Carcinoma

The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma

SOX4 in HCC
Start date: January 8, 2007
Phase:
Study type: Observational

Two hundred HCC patients with partial hepatectomy were enrolled as a cohort for observational study. The inclusion criterion was intended curative hepatectomy for HCC patients by image analysis, and the exclusion criteria were unresectable disease, synchronous cancers, recurrent cancers, or distant metastasis. The study endpoint was 30 March 2019, and tumor staging was based on the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for HCC

NCT ID: NCT04294225 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Start date: April 28, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole after surgery may prevent breast cancer from coming back (recurrence).

NCT ID: NCT04293679 Completed - Bowen's Disease Clinical Trials

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

Start date: March 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as Intralesional injection in subjects with isSCC. Goals: - To determine the safe and effective recommended dose of STP705 for the treatment of isSCC. - Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.

NCT ID: NCT04291300 Completed - Clinical trials for Adenoid Cystic Carcinoma

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

LUPSA
Start date: May 26, 2020
Phase: Phase 2
Study type: Interventional

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

NCT ID: NCT04279535 Completed - Clinical trials for Basal Cell Carcinoma

Topical Vitamin C for Treatment of Basal Cell Cancer

Start date: March 1, 2018
Phase: Early Phase 1
Study type: Interventional

Randomized coomparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment biopsy proven basal cell carcinomas inotherwise healthy adult patients. Outcome measure was biopsy proven resolution of the carcinoma.